Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | Bristol Myers Squibb Co | 174 |
| 2 | Roche Holding AG | 36 |
| 3 | Pfizer Inc | 35 |
| 4 | Alfasigma SpA | 30 |
| 5 | University of Tennessee System | 30 |
| 6 | Merck and Co Inc | 23 |
| 7 | Oncternal Therapeutics Inc | 20 |
| 8 | Centre National de la Recherche Scientifique | 16 |
| 9 | Cosciens Biopharma Inc | 16 |
| 10 | Icagen Inc | 11 |
Explore the full landscape
This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.
Visit CyprisWhere innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | A61P | Therapeutic activity (drug indications) | 533 |
| 2 | C07D | Heterocyclic compounds | 434 |
| 3 | A61K | Medicinal preparations | 320 |
| 4 | C07C | Acyclic and carbocyclic compounds | 108 |
| 5 | G01N | Investigating / analysing materials | 67 |
| 6 | C07F | Organometallic compounds | 50 |
| 7 | C12Q | Measuring/testing involving enzymes | 46 |
| 8 | C07J | 45 | |
| 9 | C07H | Sugars and derivatives | 41 |
| 10 | C07K | Peptides | 38 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionRepresentative patents
The filings that best characterise the patent activity around this compound, most-referenced first.
| Title | Year | Assignee | Cited by |
|---|---|---|---|
| Heterogeneous immunoassay for digoxin using ouabain as a separation means | 1985 | Siemens AG | 41 |
| ASSAY METHODS INVOLVING OUABAIN | 1992 | University System of Maryland | 39 |
| Antibody having binding specificity for human ouabain | 1998 | University System of Maryland | 36 |
| Immunoassay for detecting human ouabain | 1995 | 12 | |
| Ouabain triacetate derivative compounds | 1991 | Abbott Laboratories | 4 |
How research activity has moved
Papers published per year for this compound, over the last decade of indexed records.
| Year | Papers |
|---|---|
| 2016 | 61 |
| 2017 | 56 |
| 2018 | 56 |
| 2019 | 54 |
| 2020 | 43 |
| 2021 | 52 |
| 2022 | 35 |
| 2023 | 32 |
| 2024 | 28 |
| 2025 | 3 |
Who's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | Tai Akera | Michigan State University | 67 |
| 2 | John M. Hamlyn | University of Maryland, Baltimore | 56 |
| 3 | Torben Clausen | Aarhus University | 54 |
| 4 | Erland Erdmann | LMU Klinikum | 44 |
| 5 | Arnold Schwartz | Baylor College of Medicine | 39 |
| 6 | Frans H. H. Leenen | University of Ottawa | 36 |
| 7 | Amir Askari | University of Toledo Medical Center | 31 |
| 8 | Mordecai P. Blaustein | University of Maryland, Baltimore | 29 |
| 9 | Paolo Manunta | Vita-Salute San Raffaele University | 29 |
| 10 | Earl T. Wallick | University of Cincinnati Medical Center | 24 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| Two components of cardiac delayed rectifier K+ current. Differential sensitivity to block by class III antiarrhythmic agents. | 1990 | 1476 | Neuroscience and Neuropharmacology Research |
| Purification and characterization of (Na+ + K+)-ATPase III. Purification from the outer medulla of mammalian kidney after selective removal of membrane components by sodium dodecylsulphate | 1974 | 948 | Drug Transport and Resistance Mechanisms |
| Haploinsufficiency of ATP1A2 encoding the Na+/K+ pump α2 subunit associated with familial hemiplegic migraine type 2 | 2003 | 947 | Migraine and Headache Studies |
| Controlling Cardiac Chaos | 1992 | 927 | Chaos control and synchronization |
| Identification and characterization of a ouabain-like compound from human plasma. | 1991 | 784 | Ion Transport and Channel Regulation |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the molecular formula and weight of Ouabain?
Which organizations hold the most patents related to Ouabain?
What are the major research areas associated with Ouabain patents?
Who are the most prolific authors publishing research on Ouabain?
What is the publication trend for Ouabain research over the past decade?